<DOC>
	<DOCNO>NCT02749617</DOCNO>
	<brief_summary>This pilot study investigate impact dexamethasone ( DEX ) anti-Xa level participant take apixaban 2.5 mg twice day mouth ( PO BID ) . Investigators propose prospective , cohort study 24 participant multiple myeloma , lenalidomide-dexamethasone ( LEN-DEX ) -based myeloma treatment regimen indicate . Eligible participant initiate thromboprophylaxis apixaban prior start DEX-containing regimen continue end cycle 3 . Anti-Xa level , D-Dimer plasma drug concentration measure . This pilot study look investigate potential interaction apixaban dexamethasone see warrant investigation large study . The sample size 24 provide 90 % power detect primary outcome ≥ 50 % reduction peak anti-Xa level baseline . Secondary outcome include change plasma apixaban level , D-dimer , symptomatic venous thromboembolism ( VTE ) bleed 3-month treatment period .</brief_summary>
	<brief_title>A Pilot Study Investigating Apixaban Dexamethasone InterAction Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Patients diagnosis multiple myeloma accord criterion International Myeloma Working Group Patients LENDEXbased treatment regimen indicate Adult patient ≥ 19 year age able freely provide informed consent Concomitant antiplatelet anticoagulant use Calculated creatinine clearance &lt; 30 mL/min CockcroftGault formula Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal ( ULN ) Total bilirubin &gt; 2 x ULN Thrombocytopenia &lt; 50 x 10 gigalitres ( Gl ) High bleed risk spontaneously prolong prothrombin time activate partial thromboplastin time &gt; 1.5 x ULN Body weight &lt; 50 &gt; 120 kg Concomitant use CYP3A4 pglycoprotein inducer inhibitor Use Ginkgo biloba St. John 's Wort within 14 day first dose study drug Dexamethasone use within last 3 month Women Childbearing potential without proper contraceptive measure , pregnancy breast feed Life expectancy le 3 month Inability swallow issue malabsorption Any medical , social , logistical , geographical psychological factor , opinion investigator , would prohibit followup , compliance study completion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>